Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically proven acinar adenocarcinoma of the prostate
• Metastatic or locally advanced disease that either is not appropriately treated with surgery or radiation, or has recurred following previous "definitive" local therapy
• No CNS metastases
• No histologic subtypes, such as pure ductal or any component of small cell carcinoma
• Elevated PSA (at least 1.0 ng/mL in patients with prior prostatectomy or 4.0 ng/mL in those with prostate in place)
• PATIENT CHARACTERISTICS:
• Age:
• Not specified
• Performance status:
• Zubrod 0-2
• Life expectancy:
• At least 3 years
• Hematopoietic:
• Absolute neutrophil count greater than 1,500/mm\^3
• Platelet count greater than 100,000/mm\^3
• Hepatic:
• Conjugated bilirubin no greater than 0.8 mg/dL or total bilirubin no greater than 1.5 mg/dL
• Transaminase no greater than 4 times upper limit of normal
• Renal:
• Creatinine clearance at least 40 mL/min
• Cardiovascular:
• No evidence of bifascicular block on EKG
• No evidence of active ischemia on EKG
• No prior history of transient ischemic attack
• No evidence of congestive heart failure
• Other:
• No active peptic ulcer disease
• No regular use of antacid or H2 blockers
• No known or predicted achlorhydria
• No concurrent use of terfenadine, astemizole, omeprazole, or cisapride
• No second malignancy unless curatively treated
• No history of deep venous thrombosis
• No history of pulmonary embolism
• No serious co-morbidity
• HIV negative
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• No prior cytotoxic systemic therapy
• Endocrine therapy:
• Prior androgen deprivation therapy allowed if given for no more than 6 months to downstage primary
• No androgen deprivation therapy within 1 year prior to study
• Radiotherapy:
• No prior cytotoxic systemic therapy (including systemic strontium-89 irradiation)
• Prior definitive radiotherapy to the prostate and/or one metastatic site allowed
• At least 8 weeks since radiotherapy to the pelvis
• At least 3 weeks since radiotherapy to a single metastatic site
• Surgery:
• Prior prostatectomy allowed
• Other:
• No concurrent anti-anginal therapy or aggressive anticoagulants